Oncology and Hematology - MedEd On The Go

Episodes 1-16 of 87

NEW EPISODE
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 program credits
- Harry Yoon, MD
0.75 program credits
NEW EPISODE
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
0.75 program credits
- Harry Yoon, MD
- Jaffer Ajani, MD
0.75 program credits
NEW EPISODE
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 program credits
- Jaffer Ajani, MD
0.75 program credits
MinuteCE®
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
0.75 credits 3 episodes
- Harry Yoon, MD
- Jaffer Ajani, MD
0.75 credits 3 episodes
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Overcoming EGFR Resistance With HER3-Directed ADCs
Overcoming EGFR Resistance With HER3-Directed ADCs
MinuteCE®
Overcoming EGFR Resistance With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
0.75 program credits
MinuteCE®
HER3-Directed ADCs in the Treatment of EGFR-Mutated Advanced or Metastatic NSCLC Progressing on TKI and Platinum-Based Chemotherapy
0.75 credits 6 episodes
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 credits 6 episodes
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
0.75 program credits
- Pasi Antero Jänne, MD, PhD
- Helena Yu, MD
0.75 program credits
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
MinuteCE®
Biologic Rationale for Targeting HER3 and Role in EGFR Resistance
0.75 program credits
- Pasi Antero Jänne, MD, PhD
0.75 program credits
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
0.75 program credits
- Helena Yu, MD
- Pasi Antero Jänne, MD, PhD
0.75 program credits
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
CME/CE
The Weight of Recurrence: Navigating Multidisciplinary Care Planning in Recurring/Metastatic Cervical Cancer
0.25 credits
- Brian Slomovitz, MD
- Robert L. Coleman, MD, FACOG, FACS
0.25 credits
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
CME/CE Broadcast Replay
Differentiating Biomarker-Driven First-Line Treatment Strategies in Metastatic Gastric/GEJ Cancers
0.75 credits
- Nataliya Uboha, MD, PhD
0.75 credits
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
CME/CE
Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers
1.00 credit
- David H. Ilson, MD, PhD
- Sunnie Kim, MD
1.00 credit
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes

Prev
1
2
3
…
5
6
Next

1/6